Does Helicobacter pylori eradication prevent gastric cancer?

What does the largest, most recent trial tell us?

The strongest single piece of evidence comes from a 2024 cluster-randomized trial in China that enrolled over 180,000 people from 980 villages and followed them for nearly 12 years [1]. People who received a 10-day course of anti-H. pylori treatment had a 14% lower chance of developing gastric cancer compared to those who got only symptom relief (hazard ratio 0.86). When the treatment actually cleared the infection, the risk dropped even further—by 19% (hazard ratio 0.81). This means that for every 1,000 people treated, roughly 3 to 4 fewer cases of stomach cancer occurred over the study period. The trial is notable for its size and real-world community setting, making its findings directly relevant to public health policy.

How long does it take to see the benefit, and who gets the most protection?

The protective effect of eradication grows over time. A 2025 study tracking over 650,000 people across five Nordic countries found that the risk of gastric cancer was initially double that of the general population in the first 1–5 years after treatment, but it gradually fell and became virtually identical to the background population after 11 years [3]. This suggests that eradication halts the cancer-promoting effects of the infection, but it takes a decade for the risk to normalize. A 2022 trial with 26.5 years of follow-up in a high-risk Chinese region showed that people who received eradication therapy had a 43% lower incidence of gastric cancer than those on placebo (hazard ratio 0.57) [4]. The benefit was even more pronounced—a 63% risk reduction—in those who had no pre-cancerous stomach changes at the start. This means that the earlier you treat the infection, before the stomach lining is damaged, the more you stand to gain.

Why doesn't eradication always work, and what are the catches?

Despite the overall positive picture, the evidence is not uniformly straightforward. A 2024 pragmatic trial in Taiwan that invited 240,000 adults for H. pylori screening found no significant reduction in gastric cancer incidence or mortality when comparing the invited group to a control group [2]. However, when the researchers adjusted for who actually got screened and treated, they did see a 21% lower cancer rate in the screened group. This highlights a key challenge: real-world screening programs depend heavily on participation and follow-through. Additionally, the type of acid-suppressing medication used after eradication matters. A 2024 Japanese study found that people who took vonoprazan (a newer acid blocker) after H. pylori treatment had nearly double the risk of developing gastric cancer compared to those who took a different class of drug (histamine-2 receptor antagonists) [6]. The risk increased with longer use and higher doses. Finally, a 2024 study noted that a high neutrophil-to-lymphocyte ratio (a marker of inflammation) at the time of treatment predicted both eradication failure and later cancer development, suggesting that individual immune status plays a role [5]. These caveats mean that while eradication is a powerful tool, its success depends on timing, the drugs used afterward, and the patient's overall health.

About These Sources

This answer is built on 6 peer-reviewed studies — published from 2022 to 2025, 5 from 2024 or later, 4 in Q1 journals, collectively cited 329 times — selected as the most relevant from 7 studies that passed quality screening, drawn from 35 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions